Masato Ozaka

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 320 citations

S-1 Versus Gemcitabine, Gastrointestinal Oncology, Medicine +7

A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer

Masato Ozaka, Hiroshi Ishii, Tosiya Sato et al. · Cancer Chemotherapy and Pharmacology · 2018 · 155 citations

Oncology, Pancreatic Cancer, Gastrointestinal Oncology +7

Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis

Takuji Okusaka, Masahiro Yoshida, Masayuki Kitano et al. · International Journal of Clinical Oncology · 2023 · 153 citations · Full text

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)

Masato Ozaka, Yuji Matsumura, Hiroshi Ishii et al. · Cancer Chemotherapy and Pharmacology · 2012 · 85 citations

Urology, Pancreatic Cancer, S-1 Combination +7